# Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Canonical URL: https://biopharmsignal.com/news/AVTX/avalo-therapeutics-achieves-positive-topline-results-in-phase-2-lotus-trial-of-abdakibart-avtx-009-in-moderate-to-severe-hidradenitis-suppurativa
Ticker: AVTX
Company: Avalo Therapeutics
Source: Avalo Therapeutics
Published: 2026-05-05 20:01 EST
Original Source URL: https://ir.avalotx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-07 11:00 EST — [Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum-ef62dbcf) — Source: Avalo Therapeutics
- 2026-06-26 11:00 EST — [Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes-3ee6d18b) — Source: Avalo Therapeutics
- 2026-06-23 11:00 EST — [Avalo Therapeutics Appoints Ron Philip to Board of Directors](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-appoints-ron-philip-to-board-of-directors-7373732c) — Source: Avalo Therapeutics
- 2026-06-16 11:00 EST — [Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-expands-pipeline-with-avtx-010-a-long-acting-next-generation--527ab39d) — Source: Avalo Therapeutics
- 2026-05-22 20:01 EST — [Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4) — Source: Avalo Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)